Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.38 |
| ▸ | FGF2 | P09038 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12799295 | 1.00 | F2 (0.47) | F2SERPINC1FGF2 | |
| SCHEMBL4732411 | 0.96 | F2 (0.46) | F2SERPINC1FGF2 | |
| SCHEMBL12458591 | 0.88 | F2 (0.42) | F2 | |
| SCHEMBL4732589 | 0.84 | F2 (0.42) | F2 | |
| SCHEMBL12799348 | 0.84 | F2 (0.45) | F2 | |
| SCHEMBL12799315 | 0.84 | F2 (0.45) | F2 | |
| SCHEMBL12799304 | 0.84 | F2 (0.40) | F2 | |
| SCHEMBL13551195 | 0.78 | F2 (0.57) | F2SERPINC1 | |
| SCHEMBL14959577 | 0.74 | F2 (0.48) | F2SERPINC1 | |
| SCHEMBL29589310 | 0.72 | F2 (0.49) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238512-A1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | MSD OSS B.V. (NL) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238512-A1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | BRS3, SERPINC1, TBXA2R | F2 67/4885SERPINC1 2/4885FGF2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.